Model-Informed Drug Development: A Risk Firms, Regulators Need To Embrace

 
• By Sue Sutter
  
Wooden ballerina
Using modeling in drug development still requires a leap of faith.
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D